- Aptose Biosciences (TSX: APS), developing a tuspetinib-based therapy for AML, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference.
- Dr. William G. Rice, Chairman, President, and CEO, will present on May 5, 2025, at 3:00 p.m. EDT.
- The presentation will be available via webcast on the Aptose website.
Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The event is scheduled to take place in Toronto on May 5-6, 2025. Aptose is focused on developing a tuspetinib (TUS)-based triple drug frontline therapy for patients newly diagnosed with acute myeloid leukemia (AML).
Dr. William G. Rice, the Chairman, President, and CEO of Aptose, is set to deliver a corporate presentation on May 5, 2025, at 3:00 p.m. EDT. The presentation is accessible via webcast and can be found on the Aptose website. The management team will also be conducting one-on-one meetings during the conference, which interested parties can schedule through their conference representatives.
The Bloom Burton & Co. Healthcare Investor Conference provides a platform for U.S., Canadian, and international investors to engage with premier Canadian healthcare companies. It facilitates updates on company developments through presentations and private meetings.
